CTAP (0-1 mg/kg, IP, single) blocks morphine’s antinociceptive effect[1].
CTAP (10 mg/kg; IP, single) has no effect on L-DOPA-induced limb, axial, orolingual, or locomotor abnormal involuntary movements[1].
CTAP is stable in the blood and serum of rats (T1/2 > 500 min), showing that the structure of this peptide offers enzymatic resistance[2].
CTAP is extensively protein-bound to albumin in the perfusion medium (68.2%) and to proteins in rat serum (84.2%)[2].
| Animal Model: | Male Sprague-Dawley rats[1] |
| Dosage: | 0, 0.1, 0.5, 1 mg/kg |
| Administration: | IP, single |
| Result: | Completely blocked morphine’s antinociceptive effect at 0.5 or 1 mg/kg. |
